Boston Bio Systems Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve Prior Intimation for the ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Boston Commerce Ltd has informed BSE that a meeting of its Board of Directors is scheduled for Friday, 13th February 2026 at the registered office in Ahmedabad. The main item on the agenda is to consider and approve the unaudited financial results for the quarter ended 31st December 2025 (Q3 FY26). The intimation has been filed under Regulation 29 of SEBI's Listing Obligations and Disclosure Requirements. The trading window for dealing in the company's securities has been closed since 1st January 2026 and will reopen 48 hours after the results are declared. No financial figures, forecasts, or business details have been disclosed in this filing.
This is a routine pre-results regulatory filing and carries no direct financial impact on its own. Investors should watch for the actual Q3 FY26 results to be published after 13th February 2026, which could move the stock once the trading window reopens.